- Home
- GNPX vs ADVB Comparison
GNPX vs ADVB Comparison
Compare GNPX & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- ADVB
- Stock Information
- Founded
- GNPX 2009
- ADVB 2014
- Country
- GNPX United States
- ADVB United States
- Employees
- GNPX N/A
- ADVB N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- ADVB Medical Specialities
- Sector
- GNPX Health Care
- ADVB Health Care
- Exchange
- GNPX Nasdaq
- ADVB Nasdaq
- Market Cap
- GNPX 10.8M
- ADVB 9.7M
- IPO Year
- GNPX 2018
- ADVB 2025
- Fundamental
- Price
- GNPX $2.97
- ADVB $0.44
- Analyst Decision
- GNPX
- ADVB
- Analyst Count
- GNPX 0
- ADVB 0
- Target Price
- GNPX N/A
- ADVB N/A
- AVG Volume (30 Days)
- GNPX 299.4K
- ADVB 1.7M
- Earning Date
- GNPX 11-14-2025
- ADVB 11-19-2025
- Dividend Yield
- GNPX N/A
- ADVB N/A
- EPS Growth
- GNPX N/A
- ADVB N/A
- EPS
- GNPX N/A
- ADVB N/A
- Revenue
- GNPX N/A
- ADVB N/A
- Revenue This Year
- GNPX N/A
- ADVB N/A
- Revenue Next Year
- GNPX N/A
- ADVB N/A
- P/E Ratio
- GNPX N/A
- ADVB N/A
- Revenue Growth
- GNPX N/A
- ADVB N/A
- 52 Week Low
- GNPX $2.77
- ADVB $0.34
- 52 Week High
- GNPX $63.00
- ADVB $4.10
- Technical
- Relative Strength Index (RSI)
- GNPX 42.93
- ADVB 51.50
- Support Level
- GNPX $2.77
- ADVB $0.41
- Resistance Level
- GNPX $5.00
- ADVB $0.49
- Average True Range (ATR)
- GNPX 0.48
- ADVB 0.04
- MACD
- GNPX -0.27
- ADVB 0.00
- Stochastic Oscillator
- GNPX 8.07
- ADVB 59.85
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About ADVB Advanced Biomed Inc. Common Stock
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.